A Multicenter Study in Bronchoscopy Combining Stimulated Raman Histology With Artificial Intelligence for Rapid Lung Cancer Detection - The ON-SITE Study
Part of paid clinical trials in San Diego, California.
- Sponsor
- Invenio Imaging Inc.
- Study ID
- NCT07045103
- Status
- Recruiting
Conditions
- Lung Biopsy
Eligibility Criteria
- Sex
- ALL
- Age
- 22 Years - N/A
- Healthy Volunteers
- Not accepted
Study Details
The ON-SITE study represents a prospective, observational study focused on the training/tuning and pivotal validation of deep learning algorithms that detect cell/tissue morphology suspicious for cancer in biopsies of peripheral lung nodules/masses and mediastinal/hilar lymph nodes imaged with the NIO Laser Imaging System in the procedure room without requiring traditional sample processing. The study includes four arms based on biopsy location and biopsy modality/tool: 1. Transbronchial forceps biopsy of peripheral lung nodules/masses (peripheral-TBBx) 2. Transbronchial needle aspiration biopsy of peripheral lung nodules/masses (peripheral TBNA) 3. Transbronchial needle aspiration biopsy of mediastinal/hilar lymph nodes (EBUS-TBNA) 4. Transbronchial cryo biopsy of peripheral lung nodules/masses (peripheral-CBx)
Key Dates
- Start date
- Dec 21, 2023
- Status verified
- Jun 2025
- Primary completion
- Apr 30, 2026
- Completion
- May 31, 2026
Study Design
- Enrollment
- 900 participants (estimated)
Arms
- Arm: ON-SITE PatientsParticipants must fulfill all of the following criteria in order to be eligible for the study: 1. The patient or legal guardian is willing and able to understand, sign and date the Ethics committee-approved study specific Informed Consent Form. 2. The patient is 22 years of age or older. 3. The patient is scheduled for routinely indicated staging of the mediastinum (EBUS-TBNA) and planned peripheral lung biopsy procedure (peripheral-TBBx/TBNA) with an intermediate to high pretest probability of lung cancer based on clinician suspicion. 4. The patient can tolerate the clinical procedure as indicated.
Primary Outcome Measure
Peripheral TBBx and CBx Co-primary Endpoints [ Time Frame: From enrollment to the End of the Procedure. ]
Locations (7)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| UC San Diego | San Diego | California | 92037 | George Z Cheng, MD (PRINCIPAL_INVESTIGATOR) |
| Mayo Clinic Jacksonville | Jacksonville | Florida | 32224 | Bryan Husta, MD (PRINCIPAL_INVESTIGATOR) |
| Corewell Health | Grand Rapids | Michigan | 49503 | Gustavo Cumbo-Nachelli, MD (PRINCIPAL_INVESTIGATOR) |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | - |
| Montefiore Medical Center | The Bronx | New York | 10467 | Daniel Da Costa, MD (PRINCIPAL_INVESTIGATOR) |
| UNC Medical Center | Chapel Hill | North Carolina | 27514 | Jason Akulian, MD (PRINCIPAL_INVESTIGATOR) |
| MD Anderson Cancer Center | Houston | Texas | 77030 | - |